Vaccines

Five things for pharma marketers to know: Wednesday, January 17, 2018

Five things for pharma marketers to know: Wednesday, January 17, 2018

By

Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer

No Google, no problem: Pharma partners with China's tech giants

No Google, no problem: Pharma partners with China's tech giants

By

In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China's tech giants to snare a slice of a more than $100 billion market

Five things for pharma marketers to know: Thursday, January 4, 2018

Five things for pharma marketers to know: Thursday, January 4, 2018

By

Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy

Five things for pharma marketers to know: Wednesday, December 13, 2017

Five things for pharma marketers to know: Wednesday, December 13, 2017

By

Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH

Five things for pharma marketers to know: Monday, December 4, 2017

Five things for pharma marketers to know: Monday, December 4, 2017

By

CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate

Pfizer campaign aims to keep boomers healthy

Pfizer campaign aims to keep boomers healthy

By

Company enlists Patti LaBelle to increase awareness for the pneumococcal pneumonia vaccine

Five things for pharma marketers to know: Monday, November 13, 2017

Five things for pharma marketers to know: Monday, November 13, 2017

By

Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head

Five things for pharma marketers to know: Tuesday, November 7, 2017

Five things for pharma marketers to know: Tuesday, November 7, 2017

By

Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide

Five things for pharma marketers to know: Tuesday, October 31, 2017

Five things for pharma marketers to know: Tuesday, October 31, 2017

By

Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah

Five things for pharma marketers to know: Monday, October 23, 2017

Five things for pharma marketers to know: Monday, October 23, 2017

By

Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine

Infographic | The leaders of the global hepatitis-C market

Infographic | The leaders of the global hepatitis-C market

By

Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.

Top 25 vaccine products in 2016, based on U.S. sales

Top 25 vaccine products in 2016, based on U.S. sales

By

Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.

Why Sanofi's dengue fever vaccine fell short of expectations

Why Sanofi's dengue fever vaccine fell short of expectations

By

Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?

Five things for pharma marketers to know: Tuesday, July 11, 2017

Five things for pharma marketers to know: Tuesday, July 11, 2017

By

Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics

Merck campaign shows impact of shingles

Merck campaign shows impact of shingles

By

To drive the point home, the ads even feature an image of an actual case of shingles. The blistering red rash appears on-screen for several seconds.

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

By

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Pfizer expands humanitarian access to Prevnar 13 vaccine

Pfizer expands humanitarian access to Prevnar 13 vaccine

By

Pfizer expanded its humanitarian efforts by providing the Prevnar 13 vaccine at a low price and donating proceeds to aid groups.

Five things for pharma marketers to know: Monday, October 24, 2016

Five things for pharma marketers to know: Monday, October 24, 2016

By

GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus

Five things for pharma marketers to know: Wednesday, October 19, 2016

Five things for pharma marketers to know: Wednesday, October 19, 2016

By

Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market

Five things for pharma marketers to know: Monday, October 17, 2016

Five things for pharma marketers to know: Monday, October 17, 2016

By

Doctors Without Borders refuses free Pfizer vaccines; Valeant to raise prices of certain drugs; two urologists advocate for overactive bladder drugs

Five things for pharma marketers to know: Thursday, September 15, 2016

Five things for pharma marketers to know: Thursday, September 15, 2016

By

Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness

Five things for pharma marketers to know: Wednesday, August 31, 2016

Five things for pharma marketers to know: Wednesday, August 31, 2016

By

The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts

Five things for pharma marketers to know: Thursday, August 4, 2016

Five things for pharma marketers to know: Thursday, August 4, 2016

By By

Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed

Five things for pharma marketers to know: Thursday, July 21, 2016

Five things for pharma marketers to know: Thursday, July 21, 2016

By

The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers

Five things for pharma marketers to know: Thursday, July 14, 2016

Five things for pharma marketers to know: Thursday, July 14, 2016

By

The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015

Five things for pharma marketers to know: Monday, February 22, 2016

Five things for pharma marketers to know: Monday, February 22, 2016

Merck CEO says industry needs to better communicate value; procedural vote could clear Califf as FDA chief; HPV vaccine lowers virus' prevalence

Five things for pharma marketers to know: Friday, February 19, 2016

Five things for pharma marketers to know: Friday, February 19, 2016

By

Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise

Paul Newman to lead Takeda's vaccines comms

Paul Newman to lead Takeda's vaccines comms

By

The former MSL regional leader reemerges as head of communications at Japan's largest pharma company.

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

By

Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.

Five things for pharma marketers to know: Tuesday, September 15, 2015

Five things for pharma marketers to know: Tuesday, September 15, 2015

By

GSK awards its global media buying business; one-third of patients dropped out of Xenoport psoriasis trial; an experimental drug for liver disease fails to meet primary endpoints